A new analysis presented at the American Diabetes Association 68th annual scientific sessions showed US drug major Merck & Co's Januvia (sitagliptin) was associated with a 93% lower risk of having a confirmed symptomatic hypoglycemic event on a given day (p=0.001) compared to treatment with glipizide, a sulphonylurea.
This 52-week intent-to-treat analysis was based on 37 events in the sitagliptin group (n=588) and 492 events in the glipizide group (n=584). Both agents were added to ongoing metformin therapy in patients with type 2 diabetes and were associated with similar reductions in HbA1c (-0.67% in both groups at week 52 confirming non-inferiority in the prespecified per protocol analysis).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze